Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 4/20 | 0.60 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.56 |
| ▸ | REN | P00797 | 1/20 | 0.54 |
| ▸ | FURIN | P09958 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.52 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.52 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.52 |
| ▸ | NPY4R | P50391 | 3/20 | 0.51 |
| ▸ | NPY1R | P25929 | 2/20 | 0.51 |
| ▸ | NPY2R | P49146 | 2/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31528247 | 1.00 | OPRK1 (0.60) | OPRK1KISS1RRENFURINPTPN1 | |
| SCHEMBL31528272 | 0.93 | OPRK1 (0.61) | OPRK1KISS1RRENERAP2LNPEP | |
| SCHEMBL31571357 | 0.93 | OPRK1 (0.61) | OPRK1KISS1RRENERAP2LNPEP | |
| SCHEMBL30161997 | 0.93 | OPRK1 (0.61) | OPRK1KISS1RRENERAP2LNPEP | |
| SCHEMBL31134068 | 0.92 | OPRK1 (0.62) | OPRK1KISS1RRENNPY4RNPY1R | |
| SCHEMBL30769625 | 0.90 | OPRK1 (0.56) | OPRK1KISS1RPTPN1BACE1BACE2 | |
| SCHEMBL31736791 | 0.90 | OPRK1 (0.57) | OPRK1 | |
| SCHEMBL31134058 | 0.88 | NPY4R (0.61) | OPRK1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31554790 | 0.88 | NPY4R (0.62) | OPRK1KISS1RERAP2ERAP1LNPEP | |
| SCHEMBL31138045 | 0.88 | OPRK1 (0.66) | OPRK1ERAP2LNPEPNPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108452-A1 | REGENERATIVE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | INVO Aesthetics Inc. (US) | 2026-04-23 | — | — | US | claimed |
| US-20250268807-A1 | ANTI-AGING PEPTIDE CONTAINING COSMETIC | SBLA BRANDS INC. (US) | 2025-08-28 | — | — | US | claimed |
| CN-119101635-B | Helicobacter pylori resistant streptococcus salivarius subspecies thermophilus and its metaplasia and application | 山东宠言生物科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-120000588-A | Preparation method and application of marine-derived antibacterial peptide liposome | 浙江海洋大学 | 2025-05-16 | — | — | CN | claimed |
| WO-2025096781-A1 | METHODS AND COMPOSITIONS FOR PROVIDING CUSTOMIZED SKIN REGIMENS | VIBRANT HOLDINGS, LLC (US) | 2025-05-08 | — | — | WO | claimed |
| CN-119101635-A | Helicobacter pylori resistant streptococcus salivarius subspecies thermophilus and its metaplasia and application | 山东宠言生物科技有限公司 | 2024-12-10 | — | — | CN | claimed |
| WO-2024168796-A1 | USE OF EPIDERMAL GROWTH FACTOR IN PREPARATION OF DRUG FOR TREATING GASTRIC ULCER | 固德生技有限公司 | 2024-08-22 | — | — | WO | claimed |
| CN-118440968-A | Screening method of multi-copy peptide synthesis system without redundant sequence, multi-copy peptide synthesis system without redundant sequence and application | 天津凯莱英生物科技有限公司 | 2024-08-06 | — | — | CN | claimed |
| CN-117946969-B | Mesenchymal stem cell culture medium with comparison function and working method thereof | 内蒙古医科大学附属医院(内蒙古自治区心血管研究所) | 2024-07-16 | — | — | CN | claimed |
| CN-118078965-A | Chinese medicinal preparation for reducing radiation damage in medical examination | 中国人民解放军空军特色医学中心 | 2024-05-28 | — | — | CN | claimed |
| CN-114931532-A | A composition containing several plant extracts as active ingredients for relieving and relieving allergy | 杭州槿美生物科技有限公司 | 2022-08-23 | — | — | CN | claimed |
| CN-111135137-B | Periplaneta americana freeze-dried powder and preparation method and application thereof | 广州暨创医美生物科技有限公司 | 2022-08-19 | — | — | CN | claimed |
| CN-114767597-A | Composition with relieving, anti-inflammatory, anti-irritation and repairing effects and preparation method and application thereof | 广州艾玫格生物科技有限公司 | 2022-07-22 | — | — | CN | claimed |
| CN-114569508-A | Moisturizing and skin-moistening facial cream containing collagen components and preparation method thereof | 为美而生(广东)实业控股有限公司 | 2022-06-03 | — | — | CN | claimed |
| CN-110882207-B | Preparation process and method of essence for skin repair | 广州曼姗生物科技有限公司 | 2022-05-20 | — | — | CN | claimed |
| CN-114504517-A | Moisturizing essence containing collagen components and preparation method thereof | 为美而生(广东)实业控股有限公司 | 2022-05-17 | — | — | CN | claimed |
| CN-114432224-A | Caviar base membrane extraction cream and preparation process thereof | 四川荣乐化妆品有限公司 | 2022-05-06 | — | — | CN | claimed |
| US-11318077-B2 | Retinaldehyde containing compositions and methods of use | RODAN & FIELDS, LLC (US) | 2022-05-03 | — | — | US | claimed |
| CN-111939191-B | Composition for promoting angiogenesis around hair follicle and/or promoting hair growth and application | 成都天士力诺唯生物科技有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-114246820-A | Composition of night cream | 广州有容生物科技有限公司 | 2022-03-29 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108452-A1 | REGENERATIVE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | FGF1, FGF2, HGF | OPRK1 4031/4885KISS1R 2118/4885REN 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.